Literature DB >> 33409553

Chronic stress promotes acute myeloid leukemia progression through HMGB1/NLRP3/IL-1β signaling pathway.

Na Liu1, Yifan Wu1,2, Xin Wen1, Peng Li1, Fei Lu1, Hong Shang3.   

Abstract

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with poor prognosis and overall survival. Clinical investigations show that chronic stress is commonly present in the course of AML and associated with adverse outcome. However, the underlying molecular mechanisms are elusive. In the present study, a chronic restraint stress mouse model was established to evaluate the effect of stress on AML. We found that mice under chronic stress exhibited significantly increased liver and spleen infiltration of leukemic cells and poorer overall survival. This was accompanied by elevated cellular NLR family pyrin domain containing 3 (NLRP3) and interleukin-1β (IL-1β) in the liver or bone marrow, and secreted IL-1β in the plasma, indicating the activation of inflammasomes under chronic restraint stress. High mobility group box 1 (HMGB1) expression was markedly increased in newly diagnosed AML patients, but reduced in complete remission AML patients. The expression level of HMGB1 was positively correlated with NLRP3 mRNA in AML patients. Knockdown of HMGB1 significantly decreased NLRP3 and IL-1β expression in AML cell lines, and secreted IL-1β in supernatant of AML cell culture, while HMGB1 stimulation caused contrary effects. These results implied that HMGB1 could be involved in the regulation of inflammasome activation in AML development. Mice model showed that chronic restraint stress-facilitated proliferation and infiltration of AML cells were largely abrogated by knocking down HMGB1. Knockdown of HMGB1 also ameliorated overall survival and remarkably neutralized NLRP3 and IL-1β expression under chronic restraint stress. These findings provide evidences that chronic stress promotes AML progression via HMGB1/NLRP3/IL-1β dependent mechanism, suggesting that HMGB1 is a potential therapeutic target for AML. KEY MESSAGES: • Chronic restraint stress promoted acute myeloid leukemia (AML) progression and mediated NLRP3 inflammasome activation in xenograft mice. • HMGB1 mediated NLRP3 inflammasome activation in AML cells. • Knockdown of HMGB1 inhibited AML progression under chronic stress in vivo.

Entities:  

Keywords:  Acute myeloid leukemia; HMGB1; IL-1β; NLRP3; Stress

Mesh:

Substances:

Year:  2021        PMID: 33409553     DOI: 10.1007/s00109-020-02011-9

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  43 in total

Review 1.  Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator.

Authors:  Helena Erlandsson Harris; Ulf Andersson
Journal:  Eur J Immunol       Date:  2004-06       Impact factor: 5.532

Review 2.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

Review 3.  High-mobility group box 1, oxidative stress, and disease.

Authors:  Daolin Tang; Rui Kang; Herbert J Zeh; Michael T Lotze
Journal:  Antioxid Redox Signal       Date:  2011-04-01       Impact factor: 8.401

Review 4.  HMGB1 is a therapeutic target for sterile inflammation and infection.

Authors:  Ulf Andersson; Kevin J Tracey
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

Review 5.  HMGB1 and RAGE in inflammation and cancer.

Authors:  Gary P Sims; Daniel C Rowe; Svend T Rietdijk; Ronald Herbst; Anthony J Coyle
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

6.  High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity.

Authors:  John Evankovich; Sung W Cho; Ruilin Zhang; Jon Cardinal; Rajeev Dhupar; Lemeng Zhang; John R Klune; Jason Zlotnicki; Timothy Billiar; Allan Tsung
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

7.  Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms.

Authors:  Guoqian Chen; Jianhua Li; Mahendar Ochani; Beatriz Rendon-Mitchell; Xiaoling Qiang; Seenu Susarla; Luis Ulloa; Huan Yang; Saijun Fan; Sanna M Goyert; Ping Wang; Kevin J Tracey; Andrew E Sama; Haichao Wang
Journal:  J Leukoc Biol       Date:  2004-08-26       Impact factor: 4.962

Review 8.  Depression and cancer: mechanisms and disease progression.

Authors:  David Spiegel; Janine Giese-Davis
Journal:  Biol Psychiatry       Date:  2003-08-01       Impact factor: 13.382

Review 9.  Stress, depression, the immune system, and cancer.

Authors:  Edna Maria Vissoci Reiche; Sandra Odebrecht Vargas Nunes; Helena Kaminami Morimoto
Journal:  Lancet Oncol       Date:  2004-10       Impact factor: 41.316

Review 10.  Do stress-related psychosocial factors contribute to cancer incidence and survival?

Authors:  Yoichi Chida; Mark Hamer; Jane Wardle; Andrew Steptoe
Journal:  Nat Clin Pract Oncol       Date:  2008-05-20
View more
  3 in total

1.  [Effect of resveratrol on high mobility group box-1 protein signaling pathway in cartilage endplate degeneration caused by inflammation].

Authors:  Hua Hu; Liantai Li; Yanwei Liu; Shujun Wang; Shuangxi Xie; Jianjun Sun
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-04-15

Review 2.  The Impact of NLRP3 Activation on Hematopoietic Stem Cell Transplantation.

Authors:  J Luis Espinoza; Kosuke Kamio; Vu Quang Lam; Akiyoshi Takami
Journal:  Int J Mol Sci       Date:  2021-10-31       Impact factor: 5.923

Review 3.  Inflammasomes-New Contributors to Blood Diseases.

Authors:  Jaromir Tomasik; Grzegorz Władysław Basak
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.